Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.59 |
| ▸ | TLR2 | O60603 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502221 | 1.00 | DNM1 (0.59) | DNM1TLR2ALDH1A1CNR1CNR2 | |
| SCHEMBL2352070 | 0.98 | DNM1 (0.62) | DNM1TLR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL3241476 | 0.88 | DNM1 (0.60) | DNM1TLR2ALDH1A1 | |
| SCHEMBL7943647 | 0.88 | DNM1 (0.59) | DNM1TLR2ALDH1A1 | |
| SCHEMBL7943619 | 0.88 | DNM1 (0.59) | DNM1TLR2ALDH1A1 | |
| SCHEMBL7941081 | 0.88 | DNM1 (0.59) | DNM1TLR2ALDH1A1 | |
| SCHEMBL1151950 | 0.88 | DNM1 (0.59) | DNM1TLR2ALDH1A1 | |
| SCHEMBL11189857 | 0.87 | DNM1 (0.61) | DNM1TLR2ALDH1A1CNR1CNR2 | |
| SCHEMBL17263911 | 0.87 | DNM1 (0.61) | DNM1TLR2ALDH1A1CNR1CNR2 | |
| SCHEMBL5532689 | 0.87 | DNM1 (0.61) | DNM1TLR2ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200340025-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-10-29 | — | — | US | claimed |
| US-10006069-B2 | Engineered ketoreductase polypeptides | CODEXIS, INC. (US) | 2018-06-26 | — | — | US | claimed |
| US-20170226546-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-08-10 | — | — | US | claimed |
| US-9657320-B2 | Engineered ketoreductase polypeptides | CODEXIS, INC. (US) | 2017-05-23 | — | — | US | claimed |
| US-20160083759-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-03-24 | — | — | US | claimed |
| US-9228213-B2 | Polynucleotides encoding engineered ketoreductase polypeptides | CODEXIS, INC. (US) | 2016-01-05 | — | — | US | claimed |
| EP-2329013-B1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE | CODEXIS INC (US) | 2015-10-28 | — | — | EP | claimed |
| US-20150031094-A1 | POLYNUCLEOTIDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-01-29 | — | — | US | claimed |
| US-8426178-B2 | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine | CODEXIS, INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-8288141-B2 | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine | CODEXIS, INC. (US) | 2012-10-16 | — | — | US | claimed |
| EP-2329013-A2 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE | Codexis, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| US-20100173369-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE | CODEXIS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| US-20100151534-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE | CODEXIS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| WO-2010025287-A2 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE | CODEXIS, INC. (US) | 2010-03-04 | — | — | WO | claimed |
| WO-2010025238-A2 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE | CODEXIS, INC. (US) | 2010-03-04 | — | — | WO | claimed |
| CN-116217413-A | Synthesis method of key intermediate N-methyl-3-hydroxyamphetamine | 山东新时代药业有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230104779-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-04-06 | — | — | US | disclosed |
| WO-2006009884-A1 | 3-ARYLOXY-3-ARYLPROPYLAMINE SYNTHESIS | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-01-26 | — | — | WO | disclosed |
| EP-0318727-B1 | Aryloxphenylpropylamines and their preparation and use | NOVO NORDISK AS (DK) | 1994-03-09 | — | — | EP | disclosed |
| US-4296126-A | 3-Aryloxy-3-aryl-propaneamines and their method of use | ROUSSEL UCLAF (FR) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173369-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE | PNMT, KMO, RNGTT | DNM1 3929/4885TLR2 3710/4885ALDH1A1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.